Dongcheng subsidiary wins approval for prostate cancer drug clinical trial

Yantai Dongcheng Biochemicals Group Co., Ltd. announced that its controlled subsidiary, Yantai Lanna Biotech Co., Ltd., received approval from the China National Medical Products Administration on September 22, 2025, for the clinical trial of 225Ac-LNC1011 injection. The drug is intended for the treatment of advanced prostate cancer patients expressing PSMA and is set to begin clinical trials soon.

225Ac-LNC1011 injection is an alpha-particle radiopharmaceutical targeting Prostate Specific Membrane Antigen (PSMA). It is designed to deliver stronger cellular killing effects with a short range and high energy deposition, potentially minimizing damage to surrounding healthy tissues.

The company has invested approximately RMB 14,530,900 in the 225Ac-LNC1011 injection project to date. Currently, there are no similar products on the market, domestically or internationally. The drug has demonstrated promising pharmacokinetic properties and efficacy in animal and human trials, suggesting its potential as an improved treatment for metastatic castration-resistant prostate cancer (mCRPC).